Holen Sie sich die Stockscreener-App
8.25
1.73%
0.14
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - MSN
Sagimet Biosciences’ SWOT analysis: promising FASN inhibitor stock faces funding hurdles By Investing.com - Investing.com South Africa
Sagimet Biosciences’ SWOT analysis: promising FASN inhibitor stock faces funding hurdles - Investing.com
Sagimet stock holds steady as JMP reiterates $31 price target By Investing.com - Investing.com Nigeria
Sagimet Biosciences Inc: Analyzing SGMT Stock Trends - investchronicle.com
Two Sigma Investments LP Trims Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Sagimet Biosciences updates executive compensation By Investing.com - Investing.com South Africa
Sagimet Biosciences updates executive compensation - Investing.com
Sagimet Biosciences Elects New Directors at Annual Meeting - TipRanks
Sagimet Biosciences to Host Virtual KOL Event, “A New - GlobeNewswire
Sagimet Biosciences to host KOL event on denifanstat results - TipRanks
Sagimet Biosciences (SGMT) to Highlight Positive Phase 3 Acne Treatment Results | SGMT Stock News - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - The Manila Times
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - GlobeNewswire
Breakthrough Phase 3 Results: Novel Oral Acne Drug Shows Promise for 50M US Patients - Stock Titan
Analysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.17 - Defense World
Squarepoint Ops LLC Grows Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Expected to Rise, Jones Trading Analyst Says - Defense World
Sagimet Biosciences (SGMT) Price Target Raised by Jones Trading - GuruFocus
Sagimet Biosciences (SGMT) Price Target Raised by Jones Trading | SGMT Stock News - GuruFocus
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results - MSN
Sagimet Biosciences price target raised to $27 from $15 at JonesResearch - TipRanks
Sagimet Biosciences (SGMT) Target Price Raised to $27 by Analyst | SGMT Stock News - GuruFocus
Uncovering Hidden Gems: Penny Stocks To Consider In June 2025 - Yahoo Finance
Jane Street Group LLC Purchases New Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Promising Potential of Sagimet Biosciences: Buy Rating Affirmed by Positive Phase 3 Trial Results and Strategic Advancements - TipRanks
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 (SGMT) - Seeking Alpha
leerink partners maintains outperform rating on sagimet stock By Investing.com - Investing.com Canada
Sagimet Biosciences (SGMT) Surges on Successful Acne Drug Trial in China - GuruFocus
Sagimet partner Ascletis announces significant Phase III acne data - The Pharma Letter
Sector Update: Health Care - MarketScreener
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Acne Trial In China, Stock Jumps - Benzinga
leerink partners maintains outperform rating on sagimet stock - Investing.com
Sagimet Biosciences shares soar on positive acne treatment trial results By Investing.com - Investing.com South Africa
Sagimet Biosciences shares soar on positive acne treatment trial results - Investing.com
Sagimet stock climbs on acne trial data (SGMT:NASDAQ) - Seeking Alpha
Sagimet Biosciences Announces Phase 3 Trial Success - TipRanks
Sagimet Biosciences Announces Positive Phase 3 Results for - GlobeNewswire
Sagimet Biosciences Says Acne Vulgaris Treatment Meets Phase 3 Trial Primary, Secondary Endpoints - marketscreener.com
Sagimet Biosciences Announces Positive Phase 3 Results For Denifanstat - marketscreener.com
Sagimet Biosciences Reports Successful Phase 3 Results for Denifanstat in Moderate to Severe Acne and Initiates Phase 1 Trial for TVB-3567 - Nasdaq
Breakthrough Acne Treatment Achieves Phase 3 Success: First New Oral Drug Mechanism in 40 Years Shows Promise - Stock Titan
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment - Investing.com Australia
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment By Investing.com - Investing.com Nigeria
Sagimet Biosciences to host KOL event on denifanstat, resmetirom - TipRanks
Sagimet Biosciences (SGMT) to Host Key Opinion Leader Event on I - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating - GlobeNewswire
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):